Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Nonrandomized, Single-Arm Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma (CORE-MM)

NCT07637578 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT07637578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07637578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Nonrandomized, Single-Arm Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma (CORE-MM)
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2026
Completion date
February 28, 2030
Enrollment
46 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma (mm), multiple myeloma in relapse, multiple myeloma refractory